GHRP-6 vs MGF (Mechano Growth Factor)
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Growth Hormone Releasing Peptide 6, SKF-110679
GHRP-6 is a synthetic six-amino-acid peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that tricks the body into releasing its own growth hormone. It was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. It has no approval as a drug anywhere and is used only as a research compound.
Also: Mechano Growth Factor, IGF-1Ec
MGF is the name given to a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents) that muscle switches on after loading or damage. The "MGF" sold as a peptide is usually a synthetic 24-amino-acid copy of that variant's unique tail end (the E-domain, sequence YQPPSTNKNTKSQRRKGSTFEEHK), often with a modified C-terminus. It got famous through early lab work from Geoffrey Goldspink's group suggesting it kicks muscle stem cells into action. The honest picture is messier: a careful 2014 pharma replication found no effect on muscle cells at all, nobody has shown the free peptide actually exists in the body, and there are zero human trials.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- GHRP-6 has stronger research evidence (Human Trials) compared to MGF (Mechano Growth Factor) (Preclinical).
Detailed Comparison
| Attribute | GHRP-6 | MGF (Mechano Growth Factor) |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHRP-6 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor later found to be the natural target of the hunger hormone ghrelin. When it switches that receptor on in the pituitary and hypothalamus, the pituitary fires off a pulse of growth hormone. Because GHS-R1a also sits on appetite-driving neurons in the brain (the NPY/AgRP cells of the arcuate nucleus), GHRP-6 is a strong appetite stimulant, more so than the other GHRPs. At higher doses it also nudges up cortisol and prolactin, since the receptor system is not perfectly selective for the GH pathway. | The idea goes like this. When muscle is stretched or injured, the IGF-1 gene is spliced differently, producing a version with a different C-terminal E-domain. Researchers proposed that this E-domain gets cut off and acts on its own, pushing satellite cells (muscle stem cells) to multiply before mature IGF-1 tells them to fuse and build new fibers. Several studies reported that the E-peptide works without the classic IGF-1 receptor, and in heart cells it was reported to enter the cell, travel to the nucleus, and block the mitochondrial apoptosis pathway. The problem is that nobody has identified MGF's receptor, a 2010 Endocrinology review pointed out that no matching peptide has ever been isolated from cells, tissue or blood, and a 2014 study from Novartis and another drug company could not reproduce the core muscle-cell effects. So the mechanism is a hypothesis built on synthetic-peptide experiments, not established biology. |
| Common Dosing | 100-300 mcg 2-3x daily 2-3x daily | No established human dose Not established |
| Administration | Subcutaneous injection, ideally fasted | Local injection or infusion into tissue in animal studies; research-market products are injected |
| Typical Duration | 8-12 weeks | Single treatments or days to weeks in animal models; no human protocols exist |
| Best Time to Take | Before bed or morning (fasted) | Not established |
Possible Side Effects May vary by individual |
|
|
| Research Summary | GHRP-6 has been studied in humans, but mostly as a lab and diagnostic probe rather than as a treatment with large clinical trials behind it. Early work in the 1980s and 1990s showed it reliably triggers growth hormone release, and chasing its mechanism is literally what led Kojima and colleagues to discover ghrelin in 1999, which reframed how we understand hunger and GH control. A 2013 pharmacokinetic study in nine healthy men found oral bioavailability under 1 percent and an elimination half-life around 2.5 hours, which is why it is given by injection. The popular claims about muscle gain, fat loss, and healing in fitness circles are not backed by controlled human outcome trials. It is not approved by the FDA or EMA for any use and remains a research chemical, with appetite stimulation, water retention, and cortisol/prolactin bumps as known effects. | The supportive work is real but almost all in cells and animals. Yang and Goldspink (FEBS Letters, 2002) reported that the E-domain increased myoblast proliferation and delayed differentiation. Kandalla and colleagues (2011) reported it extended the proliferative lifespan of human muscle precursor cells from young donors, but not from old donors. In sheep with induced heart attacks, local MGF E-domain preserved cardiac function and cut compromised heart muscle by about 35% (Carpenter, 2008), and similar heart-protection results came from mouse studies. A gerbil stroke model showed strong neuroprotection (Dluzniewska, 2005). Then the counterpoint: Fornaro and colleagues (Am J Physiol Endocrinol Metab, 2014) tested MGF up to 500 ng/ml on mouse and human muscle cells and primary muscle stem cells and saw no effect on proliferation or differentiation, while real IGF-1 worked fine. An accompanying editorial was titled "The Fall of Mechanogrowth Factor?". In humans, the only solid data is about gene expression: heavy leg extensions raised MGF mRNA in young men but not in older men (Hameed, 2003). There are no human dosing studies and no clinical trials. One more flag: MGF E-peptide drove growth of prostate cancer cells in a lab study, and MGF was found overexpressed in prostate cancer tissue (Armakolas, 2010). |
Frequently Asked Questions: GHRP-6 vs MGF (Mechano Growth Factor)
What is the difference between GHRP-6 and MGF (Mechano Growth Factor)?
GHRP-6 is a growth hormone peptide that ghrp-6 is a synthetic six-amino-acid peptide (his-d-trp-ala-trp-d-phe-lys-nh2) that tricks the body into releasing its own growth hormone. it was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. it has no approval as a drug anywhere and is used only as a research compound. MGF (Mechano Growth Factor) is a growth hormone peptide that mgf is the name given to a splice variant of the igf-1 gene (igf-1ec in humans, igf-1eb in rodents) that muscle switches on after loading or damage. the "mgf" sold as a peptide is usually a synthetic 24-amino-acid copy of that variant's unique tail end (the e-domain, sequence yqppstnkntksqrrkgstfeehk), often with a modified c-terminus. it got famous through early lab work from geoffrey goldspink's group suggesting it kicks muscle stem cells into action. the honest picture is messier: a careful 2014 pharma replication found no effect on muscle cells at all, nobody has shown the free peptide actually exists in the body, and there are zero human trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHRP-6 or MGF (Mechano Growth Factor)?
Neither is universally "better" - the choice depends on your specific goals. GHRP-6 is typically used for growth hormone purposes, while MGF (Mechano Growth Factor) is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHRP-6 and MGF (Mechano Growth Factor) be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHRP-6 and MGF (Mechano Growth Factor) together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.